Shots:
- Lonza has agreed to divest its Capsules & Health Ingredients (CHI) business to Lone Star Funds for an enterprise value of CHF 2.3B (~$3B), receiving CHF 1.7B (~$2.2B) upfront while retaining a 40% stake with preferential participation in future exit proceeds
- Lonza is expecting total undiscounted proceeds of ≥CHF 3B (~$4B) from CHI via upfront cash, sale of the retained 40% stake & exit participation; proceeds will support CDMO-focused growth, while CHF 500M will be returned to shareholders via share buyback
- The divestment will advance Lonza’s “One Lonza” strategy to become a pure-play CDMO, following prior divestments of technologies & its small molecules micronization site in Monteggio; deal is expected to close in H2’26
Ref: Lonza | Image: Lonza and Lone Star | Press Release
Related News: Ethris Partners with Lonza to Develop Intranasal Spray-Dried mRNA Vaccines Against Respiratory Diseases
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
